SPYVLP01 + Matrix-M

SPYVLP01 + Matrix-M is a combination investigational vaccine composed of **SPYVLP01**, a virus-like particle (VLP)-based vaccine, and **Matrix-M**, a saponin-based adjuvant designed to enhance immune responses. The Matrix-M adjuvant is manufactured by Novavax and is known for its potent immunostimulatory properties, improving both the magnitude and quality of the immune response to protein subunit and VLP vaccines. The precise target and indication for SPYVLP01 are not confirmed in the currently available literature, but the naming convention and inclusion of Matrix-M suggest it is in early-stage development, likely as a prophylactic vaccine for an infectious disease or other indication where VLPs are applicable. Detailed mechanistic and clinical development information about SPYVLP01 is not available in the provided search results.